Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) CEO Steven Gourlay joins Jonathan Jackson in the Proactive studio to discuss the company's focus on neuro therapeutics and to review the highlights from the first half of the financial year. Steven brings a wealth of experience from the biotech industry, including as founding chief medical officer of Principia Biopharma Inc, which sold to Sanofi for $3.7 billion in 2020. Gourlay details the company’s work in developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. The company is developing its lead compound, Xanamem®, a new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. He takes us through current clinical trials, the company’s strong financial position and outlines the strategic priorities for the next 18 months, giving investors an idea of what to expect moving forward.
Actinogen Medical delivers strong half-year results as it develops novel therapy
